Covid-19 and Inflammation
Scientific publications from GREMI members
Inflammation / Immunity
Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity.
Flament et al., Nat Immunol. 2021 Mar;22(3):322-335.
Phenotypical and functional alteration of unconventional T cells in severe COVID-19 patients
Jouan et al., J Exp Med. 2020 Dec 7;217(12):e20200872.
Autoantibodies against type I IFNs in patients with life-threatening COVID-19.
Bastard et al., Science. 2020 Oct 23;370(6515):eabd4585.
Broad-spectrum antiviral activity of naproxen: from Influenza A to SARS-CoV-2 Coronavirus
Terrier et al., bioRxiv (preliminary report) 2020.
Proteinase release from activated neutrophils in mechanically ventilated patients with non-COVID-19 and COVID-19 pneumonia.
Seren et al., Eur Respir J. 2021 Jan 8:2003755.
Pulmonary immune responses against SARS-CoV-2 infection: harmful or not?
Guillon et al., Intensive Care Med. 2020 Oct;46(10):1897-1900.
Controlled Heat and Humidity-Based Treatment for the Reuse of Personal Protective Equipment: A Pragmatic Proof-of-Concept to Address the Mass Shortage of Surgical Masks and N95/FFP2 Respirators and to Prevent the SARS-CoV2 Transmission.
Bernard et al., Front Med (Lausanne). 2020 Oct 20;7:584036.
Tackling osteoarthritis during COVID-19 pandemic.
Castro da Rocha et al., Ann Rheum Dis. 2021 Feb;80(2):151-153.
Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis.
COVID-19 Global Rheumatology Alliance. Putman et al., Arthritis Rheumatol. 2021 Jan;73(1):36-47.
Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19.
Sattui et al., Expert Rev Clin Immunol. 2020 Jul;16(7):659-666.
Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist.
COVID-19 Global Rheumatology Alliance. Graef et al., Ann Rheum Dis. 2020 Jun;79(6):734-736.
A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19.
Kim et al., Ann Intern Med. 2020 Jun 16;172(12):819-821.
Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020. Richez et al., Joint Bone Spine. 2020 Oct;87(5):431-437.
Steroids: A Therapeutic Option for COVID-19 Pneumonia Patients With ESRD?
Delafosse et al., Kidney Int Rep. 2020 Jun 17;5(8):1375.
Lopinavir-Ritonavir Associated Acute Kidney Injury Is Not Related to Crystalluria in Critically Ill COVID-19 Patients.
Arrestier et al., Kidney Int Rep. 2020 Nov;5(11):2119.
Other scientific publications
Dexamethasone in Hospitalized Patients with Covid-19.
RECOVERY Collaborative Group, N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans.
Arunachalam et al., Science. 2020 Sep 4;369(6508):1210-1220.
Influenza infection, SARS, MERS and COVID-19: Cytokine storm - The common denominator and the lessons to be learned.
Ryabkova et al., Clin Immunol. 2021 Feb;223:108652.
SARS-CoV-2 infection of Chinese hamsters (Cricetulus griseus) reproduces COVID-19 pneumonia in a well-established small animal model.
Bertzbach et al., Transbound Emerg Dis. 2020 Sep 18:10.1111/tbed.13837.
The Roborovski Dwarf Hamster Is A Highly Susceptible Model for a Rapid and Fatal Course of SARS-CoV-2 Infection.
Trimpert et al., Cell Rep. 2020 Dec 8;33(10):108488.